CC 10004

Known as: CC-10004, CC10004 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2012
0120042012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A broad range of treatments for psoriasis are available, including topical treatments (vitamin D, corticosteroids, calcineurin… (More)
Is this relevant?
2009
2009
BACKGROUND Thalidomide, one of whose activities is to inhibit Tumour Necrosis Factor (TNF)-α production, has been reported to be… (More)
Is this relevant?
Review
2007
Review
2007
The phosphodiesterase (PDE) 4 is the predominant cyclic AMP degrading enzyme in a variety of inflammatory cells including… (More)
  • table 1
Is this relevant?
Review
2005
Review
2005
CC-10004, a phosphodiesterase 4 inhibitor and selective cytokine inhibitor, is under development by Celgene for the potential… (More)
Is this relevant?
Review
2005
Review
2005
CC-1088, a thalidomide analog inhibitor of phosphodiesterase 4, was being developed by Celgene for the potential treatment of… (More)
Is this relevant?
2004
2004
Myeloma cells and human umbilical vein endothelial cells (HUVECs) were co-cultured to model in vitro the interactions between… (More)
Is this relevant?